NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 3, 2026Sponsor estimate | NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate Cancer | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 23, 2026Sponsor estimate | NCT05849298A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNovartis Pharmaceuticals · Prostatic Neoplasm | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT06388941Iptacopan in Patients With ANCA Associated VasculitisNovartis Pharmaceuticals · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT05849298A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNovartis Pharmaceuticals · Prostatic NeoplasmActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06388941Iptacopan in Patients With ANCA Associated VasculitisNovartis Pharmaceuticals · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 25, 2027Sponsor estimate | NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid Tumors | NVSLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT04544189Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and...Novartis Pharmaceuticals · Breast Neoplasms | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 25, 2027Sponsor estimatePhase 1/Phase 2NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid TumorsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 2NCT04544189Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and...Novartis Pharmaceuticals · Breast NeoplasmsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT02934568Ribociclib (LEE011) Rollover Study for Continued AccessNovartis Pharmaceuticals · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 2, 2027Sponsor estimate | NCT04417621Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNovartis Pharmaceuticals · Melanoma | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 4, 2027Sponsor estimate | NCT07811908Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum...Novartis Pharmaceuticals · Uncomplicated Plasmodium Falciparum Malaria | NVSLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT02934568Ribociclib (LEE011) Rollover Study for Continued AccessNovartis Pharmaceuticals · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2027Sponsor estimatePhase 2NCT04417621Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNovartis Pharmaceuticals · MelanomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2027Sponsor estimatePhase 2NCT07811908Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum...Novartis Pharmaceuticals · Uncomplicated Plasmodium Falciparum MalariaRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.